Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14821764 | 0.98 | POLB (0.46) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16867095 | 0.83 | ALDH1A1 (0.48) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| Bromide SCHEMBL7918168 | 0.82 | PPARG (0.44) | POLBALDH1A1PPARGL3MBTL1HSD17B10 | |
| SCHEMBL16870810 | 0.80 | PPARG (0.48) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22074459 | 0.79 | POLB (0.47) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| Bromide SCHEMBL3576414 | 0.76 | KDM4E (0.50) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3576418 | 0.74 | KDM4E (0.51) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11168282 | 0.71 | POLB (0.48) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3044303 | 0.70 | LPAR1 (0.36) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20037274 | 0.69 | ALDH1A1 (0.50) | POLBALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757882-B1 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | disclosed |
| US-9518055-B2 | Imidazopyridyl compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160031882-A1 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-02-04 | — | — | US | disclosed |
| US-9173873-B2 | — | — | 2015-11-03 | — | — | US | disclosed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140235667-A1 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-08-21 | — | — | US | disclosed |
| EP-2757882-A1 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043518-A1 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235667-A1 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | NR3C2, CYP21A2, HSD11B1 | POLB 3007/4885ALDH1A1 225/4885CYP1A2 66/4885 |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | POLB 1182/4885ALDH1A1 4785/4885CYP1A2 2264/4885 |
| US-20160031882-A1 | IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | NR3C2, CYP21A2, HSD11B1 | POLB 2938/4885ALDH1A1 257/4885CYP1A2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.